论文部分内容阅读
目的探讨胰岛素抵抗与非胰岛素抵抗多囊卵巢综合征的临床疗效。方法 92例多囊卵巢综合征患者,按治疗方法不同分为非胰岛素抵抗组和胰岛素抵抗组,各46例。非胰岛素抵抗组采取常规治疗,胰岛素抵抗组在常规治疗基础上采取二甲双胍治疗,观察两组体质量指数(BMI)、血脂与性激素水平。结果胰岛素抵抗组患者促黄体生成素(LH)、促卵泡生成素(FSH)、雌二醇(E2)水平分别为(0.26±0.15)、(0.95±0.58)U/L、(0.21±0.12)ng/L均明显低于与非胰岛素抵抗组的(0.48±0.19)、(1.29±0.38)U/L、(0.37±0.19)ng/L,差异具有统计学意义(P<0.05)。胰岛素抵抗组患者的甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、BMI水平与非胰岛素抵抗组比较差异具有统计学意义(P<0.05),两组总胆醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平比较差异无统计学意义(P>0.05)。结论多囊卵巢综合征患者存在胰岛素抵抗时更易出现血脂代谢障碍,对其胰岛素抵抗状态进行调节,对临床治疗有重要意义。
Objective To investigate the clinical efficacy of insulin resistance and non-insulin resistance polycystic ovary syndrome. Methods Ninety-two patients with PCOS were divided into non-insulin resistance group and insulin resistance group according to different treatment methods, 46 cases in each group. Non-insulin resistance group to take conventional treatment, insulin resistance group treated with metformin on the basis of conventional treatment, body mass index (BMI), serum lipids and sex hormone levels were observed. Results The levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) and estradiol (E2) in patients with insulin resistance were (0.26 ± 0.15), (0.95 ± 0.58) U / (0.48 ± 0.19), (1.29 ± 0.38) U / L, (0.37 ± 0.19) ng / L, respectively. The difference was statistically significant (P <0.05). The levels of triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and BMI in insulin resistance group were significantly different from non-insulin resistance group (P <0.05) , While there was no significant difference in the level of LDL-C (P> 0.05). Conclusions Patients with polycystic ovary syndrome are more likely to have dyslipidemia in the presence of insulin resistance and their insulin resistance status is regulated, which is of great significance for clinical treatment.